Priothera Strengthens Board with Dr. Hans Menssen's Appointment

Company - People | Jun 03, 2025 | Fountain Healthcare Partners L

Priothera Strengthens Board with Dr. Hans Menssen's Appointment

Priothera Ltd., a prominent biopharmaceutical firm focusing on sphingosine 1 phosphate (S1P) receptor modulators for hematologic ailments, has announced the appointment of Dr. Hans Menssen to its Board of Directors. Dr. Menssen, formerly Senior Global Program Clinical Head at Novartis Oncology, commands global acclaim for his extensive experience in overseeing critical clinical programs concentrated on acute myeloid leukemia (AML), among other conditions. Priothera is embracing his expertise to advance their flagship mocravimod—a novel oral S1P receptor modulator—through a pivotal Phase 3 trial for AML patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HCT). Florent Gros, E.O. of Priothera, highlighted that Dr. Menssen's appointment aligns with the company's strategy to leverage seasoned insights in global drug development, thereby paving the way for mocravimod's successful market introduction. Dr. Menssen’s professional journey encompasses pivotal roles at Bayer Schering Pharma and Philogen SpA, fueling oncology innovations across various therapeutic areas. The addition of Dr. Menssen marks a crucial step in Priothera's mission to improve treatment outcomes for AML patients through innovative therapeutic avenues.

Sectors

  • Biotechnology
  • Health Care

Geography

  • Ireland – Priothera Ltd. is based in Ireland, indicating the geographic origin of the company and its operations.
  • Switzerland – Dr. Menssen has academic ties in Switzerland, reflecting part of his extensive educational background.

Industry

  • Biotechnology – The article involves Priothera, a biopharmaceutical company pioneering therapeutic developments in hematologic diseases, thus it falls under the Biotechnology sector.
  • Health Care – Dr. Hans Menssen's expertise in clinical development and his role in advancing Priothera's treatment for hematologic malignancies signifies relevance to the Health Care sector.

Financials

    Participants

    NameRoleTypeDescription
    Priothera Ltd.Target CompanyCompanyA late-stage biopharmaceutical firm focusing on innovative treatments for hematologic malignancies.
    Dr. Hans MenssenBoard MemberPersonNewly appointed board member of Priothera, bringing extensive clinical development experience, particularly in oncology.
    Fountain Healthcare PartnersInvestorCompanyA private equity firm managing Priothera's advancements as part of their investment portfolio.
    Florent GrosCEO of PriotheraPersonCo-Founder and CEO of Priothera, overseeing the strategic direction of the company.